189 related articles for article (PubMed ID: 26544874)
1. Cytochrome P450 Oxidoreductase Influences CYP2B6 Activity in Cyclophosphamide Bioactivation.
El-Serafi I; Afsharian P; Moshfegh A; Hassan M; Terelius Y
PLoS One; 2015; 10(11):e0141979. PubMed ID: 26544874
[TBL] [Abstract][Full Text] [Related]
2. Effects of the selected cytochrome P450 oxidoreductase genetic polymorphisms on cytochrome P450 2B6 activity as measured by bupropion hydroxylation.
Lv J; Hu L; Zhuo W; Zhang C; Zhou H; Fan L
Pharmacogenet Genomics; 2016 Feb; 26(2):80-7. PubMed ID: 26580670
[TBL] [Abstract][Full Text] [Related]
3. The P450 oxidoreductase (POR) rs2868177 and cytochrome P450 (CYP) 2B6*6 polymorphisms contribute to the interindividual variability in human CYP2B6 activity.
Gao LC; Liu FQ; Yang L; Cheng L; Dai HY; Tao R; Cao SP; Wang D; Tang J
Eur J Clin Pharmacol; 2016 Oct; 72(10):1205-1213. PubMed ID: 27439448
[TBL] [Abstract][Full Text] [Related]
4. Stereoselective Bupropion Hydroxylation by Cytochrome P450 CYP2B6 and Cytochrome P450 Oxidoreductase Genetic Variants.
Wang PF; Neiner A; Kharasch ED
Drug Metab Dispos; 2020 Jun; 48(6):438-445. PubMed ID: 32238417
[TBL] [Abstract][Full Text] [Related]
5. Methadone pharmacogenetics in vitro and in vivo: Metabolism by CYP2B6 polymorphic variants and genetic variability in paediatric disposition.
Wang PF; Sharma A; Montana M; Neiner A; Juriga L; Reddy KN; Tallchief D; Blood J; Kharasch ED
Br J Clin Pharmacol; 2022 Nov; 88(11):4881-4893. PubMed ID: 35538637
[TBL] [Abstract][Full Text] [Related]
6. Stereoselective Ketamine Metabolism by Genetic Variants of Cytochrome P450 CYP2B6 and Cytochrome P450 Oxidoreductase.
Wang PF; Neiner A; Kharasch ED
Anesthesiology; 2018 Oct; 129(4):756-768. PubMed ID: 30085944
[TBL] [Abstract][Full Text] [Related]
7. Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation.
Code EL; Crespi CL; Penman BW; Gonzalez FJ; Chang TK; Waxman DJ
Drug Metab Dispos; 1997 Aug; 25(8):985-93. PubMed ID: 9280407
[TBL] [Abstract][Full Text] [Related]
8. Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants.
Vredenburg G; den Braver-Sewradj S; van Vugt-Lussenburg BM; Vermeulen NP; Commandeur JN; Vos JC
Toxicol Lett; 2015 Jan; 232(1):182-92. PubMed ID: 25448283
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450 2B6*5 Increases Relapse after Cyclophosphamide-Containing Conditioning and Autologous Transplantation for Lymphoma.
Bachanova V; Shanley R; Malik F; Chauhan L; Lamba V; Weisdorf DJ; Burns LJ; Lamba JK
Biol Blood Marrow Transplant; 2015 May; 21(5):944-8. PubMed ID: 25677220
[TBL] [Abstract][Full Text] [Related]
10. Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles.
Roy P; Yu LJ; Crespi CL; Waxman DJ
Drug Metab Dispos; 1999 Jun; 27(6):655-66. PubMed ID: 10348794
[TBL] [Abstract][Full Text] [Related]
11. Effect of P450 Oxidoreductase Polymorphisms on the Metabolic Activities of Ten Cytochrome P450s Varied by Polymorphic CYP Genotypes in Human Liver Microsomes.
Fang Y; Gao N; Tian X; Zhou J; Zhang HF; Gao J; He XP; Wen Q; Jia LJ; Jin H; Qiao HL
Cell Physiol Biochem; 2018; 47(4):1604-1616. PubMed ID: 29949783
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetic Influence on Stereoselective Steady-State Disposition of Bupropion.
Kharasch ED; Lenze EJ
Drug Metab Dispos; 2024 Apr; 52(5):455-466. PubMed ID: 38467432
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome P450 Genetic Variations Can Predict mRNA Expression, Cyclophosphamide 4-Hydroxylation, and Treatment Outcomes in Chinese Patients With Non-Hodgkin's Lymphoma.
Shu W; Chen L; Hu X; Zhang M; Chen W; Ma L; Liu X; Huang J; Pang T; Li J; Zhang Y
J Clin Pharmacol; 2017 Jul; 57(7):886-898. PubMed ID: 28181240
[TBL] [Abstract][Full Text] [Related]
14. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes.
Chang TK; Weber GF; Crespi CL; Waxman DJ
Cancer Res; 1993 Dec; 53(23):5629-37. PubMed ID: 8242617
[TBL] [Abstract][Full Text] [Related]
15. Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy.
Jounaidi Y; Hecht JE; Waxman DJ
Cancer Res; 1998 Oct; 58(19):4391-401. PubMed ID: 9766669
[TBL] [Abstract][Full Text] [Related]
16. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
Patterson LH; McKeown SR; Robson T; Gallagher R; Raleigh SM; Orr S
Anticancer Drug Des; 1999 Dec; 14(6):473-86. PubMed ID: 10834269
[TBL] [Abstract][Full Text] [Related]
17. Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches.
Venkatakrishnan K; von Moltke LL; Court MH; Harmatz JS; Crespi CL; Greenblatt DJ
Drug Metab Dispos; 2000 Dec; 28(12):1493-504. PubMed ID: 11095589
[TBL] [Abstract][Full Text] [Related]
18. [Cyclophosphamide and CYP2B6].
Torimoto Y; Kohgo Y
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1090-3. PubMed ID: 18633247
[TBL] [Abstract][Full Text] [Related]
19. Effect of Cytochrome b5 Content on the Activity of Polymorphic CYP1A2, 2B6, and 2E1 in Human Liver Microsomes.
Zhang H; Gao N; Liu T; Fang Y; Qi B; Wen Q; Zhou J; Jia L; Qiao H
PLoS One; 2015; 10(6):e0128547. PubMed ID: 26046844
[TBL] [Abstract][Full Text] [Related]
20. Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients.
Helsby N; Yong M; Burns K; Findlay M; Porter D
Cancer Chemother Pharmacol; 2021 Sep; 88(3):533-542. PubMed ID: 34114066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
